Colchicine and Leukopenia: Clinical Implications - 19/08/20
Doi : 10.1016/j.jpeds.2020.03.065
Erdal Sag, MD 1, ∗, Yagmur Bayindir, MD 1, ∗, Aydin Adiguzel, MD 1, Selcan Demir, MD 1, Yelda Bilginer, MD 1, Selin Aytac, MD 2, Seza Ozen, MD 1, ⁎ 
1 Division of Pediatric Rheumatology, Department of Pediatrics, Ankara, Turkey
2 Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University, Ankara, Turkey
∗Reprints requests: Seza Ozen, MD, Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey.Department of PediatricsDivision of RheumatologyHacettepe University Faculty of MedicineAnkara06100Turkey
Abstract |
Colchicine is the mainstay of treatment for familial Mediterranean fever. We investigated the frequency of leukopenia in 213 patients with familial Mediterranean fever treated with standard doses of colchicine (0.5-2.0 mg/day). We found that 23 patients (10.8%) had reversible leukopenia, 3 moderate, and none severe and that their rate of infections was not increased.
Le texte complet de cet article est disponible en PDF.Keywords : colchicine, leukopenia, FMF
Abbreviation : FMF
Plan
| The authors declare no conflicts of interest. |
© 2020
Elsevier Inc. Tous droits réservés.
Vol 224
P. 166 - septembre 2020 Retour au numéro
Article précédent
- Cardiovascular Risk Markers and Cognitive Performance in Children
- Sebastian Ludyga, Sabrina Köchli, Markus Gerber, Oliver Faude, Lukas Zahner, Henner Hanssen
- Listen to Your Patients: A Diagnostic Clue
- Fiorentino Grasso, Rita Genesio, Nicola Brunetti-Pierri
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?